agilon health, inc.(AGL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,626 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AGL Stock Analysis & AI Quality Score
AI stock analysis and institutional research for agilon health, inc. (AGL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AGL at 46.9/100 on a 32-signal composite quality model, placing it at rank #1,626 of 2,879 stocks — the bottom half of the AI-ranked universe. AGL scores in the top quartile across institutional flow (84.0), revenue scale (80.1). Areas of concern include balance sheet strength (15.6) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), agilon health, inc. reports quarterly revenue of $1.4B, net income of $48.9M, free cash flow of $20.6M. Top institutional holders of AGL by reported 13-F value include Clayton, Dubilier & Rice,, MORGAN STANLEY, North Peak Capital Management,, based on the most recent SEC filings. AGL trades on the NYSE exchange and files with the SEC under CIK 1831097. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for agilon health, inc. directly from SEC EDGAR. agilon health, inc.'s 13F Pro composite quality score has ranged between 39 and 55 since 2022, currently 46.9 — an improving long-term trajectory across 24 quarterly and live scoring snapshots.
Revenue
Q1 2026
$1.4B
Net Income
Q1 2026
$48.9M
Free Cash Flow
Q1 2026
$20.6M
D/E Ratio
Q1 2026
0.17
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-2.1% YoYNet Income
-50.4% YoYOperating Income
-58.6% YoYTotal Assets
-26.7% YoYTotal Debt
+55.4% YoYOp. Cash Flow
-83.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $5.93B -2.1% | $6.06B +40.4% | $4.32B +80.7% | $2.39B +96.0% | $1.22B +53.4% | $794.4M |
| Net Income | $-391.3M -50.4% | $-260.2M +0.9% | $-262.6M -146.4% | $-106.6M -77.4% | $-60.1M +78.7% | $-282.6M |
| Operating Income | $-463.2M -58.6% | $-292.1M -25.8% | $-232.1M -120.3% | $-105.4M -85.9% | $-56.7M +46.8% | $-106.6M |
| Total Assets | $1.27B -26.7% | $1.73B -0.4% | $1.74B +2.6% | $1.70B +280.3% | $446.4M | — |
| Total Debt | $54.2M +55.4% | $34.9M -22.1% | $44.8M -8.1% | $48.8M -28.0% | $67.7M | — |
| Operating Cash Flow | $-105.8M -83.1% | $-57.8M +63.0% | $-156.2M -19.4% | $-130.8M -145.9% | $-53.2M +48.8% | $-103.9M |
Get alerted when AGL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for agilon health, inc. including:
Top Institutional Holders of AGL
Clayton, Dubilier & Rice, LLC
$31.6M4,000,000 shMORGAN STANLEY
$16.6M2,099,451 shNorth Peak Capital Management, LLC
$12.2M1,545,537 shGOLDMAN SACHS GROUP INC
$8.4M1,062,236 shAQR CAPITAL MANAGEMENT LLC
$7.7M974,897 shBlackRock, Inc.
$6.9M873,164 shD. E. Shaw & Co., Inc.
$5.9M742,218 shVANGUARD CAPITAL MANAGEMENT LLC
$4.3M538,536 shCHARLES SCHWAB INVESTMENT MANAGEMENT INC
$2.9M364,499 shJACOBS LEVY EQUITY MANAGEMENT, INC
$2.3M296,552 sh
| Fund | Value | Shares |
|---|---|---|
| Clayton, Dubilier & Rice, LLC | $31.6M | 4,000,000 |
| MORGAN STANLEY | $16.6M | 2,099,451 |
| North Peak Capital Management, LLC | $12.2M | 1,545,537 |
| GOLDMAN SACHS GROUP INC | $8.4M | 1,062,236 |
| AQR CAPITAL MANAGEMENT LLC | $7.7M | 974,897 |
| BlackRock, Inc. | $6.9M | 873,164 |
| D. E. Shaw & Co., Inc. | $5.9M | 742,218 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.3M | 538,536 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2.9M | 364,499 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2.3M | 296,552 |
More Healthcare Companies
View all Healthcare →Put AGL on your watchlist
Track score changes the day agilon health, inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AGL a good stock to buy?
13F Pro's AI-powered analysis of agilon health, inc. (AGL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AGL are available on the AGL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AGL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AGL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of agilon health, inc.'s investment landscape.